logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 11084861 B1

PDFFull Text
Date of Patent:
Aug. 10, 2021

Filed:

Jul. 22, 2019

Gip/glp1 co-agonist compounds

Applicant:

Eli Lilly and Company, Indianapolis, IN (US);

Inventors:

Milata Mary Abraham, Indianapolis, IN (US);

Jorge Alsina-Fernandez, Indianapolis, IN (US);

Robert Andrew Brown, Carmel, IN (US);

Over Cabrera, Carmel, IN (US);

Tamer Coskun, Carmel, IN (US);

Robert Chadwick Cummins, Carmel, IN (US);

Mohamed ElSayed Hamed Elsayed, Fishers, IN (US);

Hongchang Qu, Carmel, IN (US);

James Lincoln Wallis, Indianapolis, IN (US);

Amita Datta-Mannan, Indianapolis, IN (US);

Xianyin Lai, Carmel, IN (US);

Assignee:

Eli Lilly and Company, Indianapolis, IN (US);

Attorney:

Macharri Vorndran-Jones

Primary Examiner:

Maury A Audet

Int. Cl.
CPC ...
C07K 14/605 (2006.01); A61P 3/04 (2006.01); A61K 9/20 (2006.01); A61K 9/48 (2006.01); A61K 38/56 (2006.01); A61K 9/00 (2006.01);
U.S. Cl.
CPC ...
C07K 14/605 (2013.01); A61K 9/2013 (2013.01); A61K 9/4858 (2013.01); A61K 38/56 (2013.01); A61P 3/04 (2018.01); A61K 9/0019 (2013.01); A61K 9/0053 (2013.01);
Abstract

The present invention relates to compounds having activity at both the human glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. The present invention also relates to compounds having an extended duration of action at each of these receptors. Furthermore, the present invention relates to compounds that may be administered orally. Compounds may be useful in the treatment of type 2 diabetes mellitus ('T2DM'). Also, the compounds may be useful in the treatment of obesity.

Find Patent Forward Citations

Abraham, Milata. (2021). Gip/glp1 co-agonist compounds (U.S. Patent No. 11084861). U.S. Patent and Trademark Office. https://idiyas.com/patent/badge/11084861

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Loading…